Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
0–14
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females, ages 3 months through 14 years inclusive
Receiving antibiotics for suspected or proven infection
You may not be if
Body weight greater than 45 kg
Patients taking anti-seizure medications within 30 days of moxifloxacin dosing
Known or suspected allergy to quinolones
History of tendon disease/disorder related to quinolone treatment
Severe, life-threatening disease with a life expectancy of less than 48 hours and/or known rapidly fatal underlying disease (death expected within 2 months)
Abnormal musculoskeletal evaluation at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)
Cardiac arrhythmia
Evidence of renal or hepatic disease, based on laboratory findings (serum creatinine, total bilirubin, or ALT, \> 1.5 times upper limit of normal) and physical exam
Patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents
Patients taking any medication known to increase the QT interval, eg, amiodarone, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, disopyuramide, dofetilide, droperidol, halofantrine, haloperidol, ibutilide, levomethadyl, mesoradazine, methadone, pimozide, procainamide, quinidine, sotalol, terfenadine
Pregnancy
Clinically relevant findings in the ECG
Participation in another clinical study during the preceding 30 days1 (last treatment from previous study to first treatment of new study)
Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the patient's safety
Patients taking another fluoroquinolone at the time of planned moxifloxacin dosing
